Related Experiment Videos
Carbamazepine trial for Lesch-Nyhan self-mutilation
E S Roach1, M Delgado, L Anderson
1Divison of Pediatric Neurology, University of Texas Southwestern Medical School, Dallas 75235, USA.
Journal of Child Neurology
|November 1, 1996
Summary
Carbamazepine may reduce self-mutilation in Lesch-Nyhan syndrome patients. This study observed diminished self-harm and restraint needs in four boys treated with carbamazepine, suggesting a potential central nervous system effect.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Lesch-Nyhan syndrome is a rare genetic disorder.
- Self-mutilation is a hallmark symptom of Lesch-Nyhan syndrome.
- Anticonvulsants are being explored for managing self-harm behaviors.
Purpose of the Study:
- To investigate the efficacy of carbamazepine in reducing self-mutilation in patients with Lesch-Nyhan syndrome.
- To explore potential underlying mechanisms, including sensory neuropathy.
Main Methods:
- Nerve and muscle biopsies were performed on four patients with Lesch-Nyhan syndrome.
- An uncontrolled pilot trial using carbamazepine was conducted.
- Clinical features and enzyme analysis confirmed the diagnosis.
Main Results:
- No specific abnormalities were found in nerve or muscle biopsies.
- Self-mutilation and the need for restraint decreased in all four patients.
- Two patients experienced increased self-mutilation upon carbamazepine discontinuation and improvement upon re-initiation.
Conclusions:
- Carbamazepine may effectively reduce self-mutilation in Lesch-Nyhan syndrome.
- The therapeutic effect is likely mediated by the central nervous system, not sensory neuropathy.
- Further research is warranted to confirm these findings and elucidate mechanisms.